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The changes of immunoglobulin 
G N-glycosylation in blood lipids 
and dyslipidaemia
Di Liu1†, Xi Chu2†, Hao Wang1,3, Jing Dong2, Si‑Qi Ge1,3, Zhong‑Yao Zhao1, Hong‑Li Peng1, Ming Sun1, 
Li‑Juan Wu1, Man‑Shu Song1, Xiu‑Hua Guo1, Qun Meng1, You‑Xin Wang1,3* , Gordan Lauc4,5 and Wei Wang1,3
Abstract 
Background: Alternative N‑glycosylation has significant structural and functional consequences on immunoglobulin 
G (IgG) and can affect immune responses, acting as a switch between pro‑ and anti‑inflammatory IgG functionality. 
Studies have demonstrated that IgG N‑glycosylation is associated with ageing, body mass index, type 2 diabetes and 
hypertension.
Methods: Herein, we have demonstrated patterns of IgG glycosylation that are associated with blood lipids in a 
cross‑sectional study including 598 Han Chinese aged 20–68 years. The IgG glycome composition was analysed by 
ultra‑performance liquid chromatography.
Results: Blood lipids were positively correlated with glycan peak GP6, whereas they were negatively correlated 
with GP18 (P < 0.05/57). The canonical correlation analysis indicated that initial N‑glycan structures, including GP4, 
GP6, GP9‑12, GP14, GP17, GP18 and GP23, were significantly correlated with blood lipids, including total cholesterol, 
total triglycerides (TG) and low‑density lipoprotein (r = 0.390, P < 0.001). IgG glycans patterns were able to distin‑
guish patients with dyslipidaemia from the controls, with an area under the curve of 0.692 (95% confidence interval 
0.644–0.740).
Conclusions: Our findings indicated that a possible association between blood lipids and the observed loss of galac‑
tose and sialic acid, as well as the addition of bisecting GlcNAcs, which might be related to the chronic inflammation 
accompanying with the development and procession of dyslipidaemia.
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Background
Glycosylation is an essential posttranslational modifi-
cation of proteins. It is an integral part of proteins and 
significantly contributes to their structure and function 
[1–3]. Immunoglobulin G (IgG) plays an important role 
in the human immune system, and N-glycans attach to 
the conserved asparagine 297 in the fragment crystalliza-
ble (Fc) part of this molecule and act as a switch between 
pro- and anti-inflammatory IgG functionality [1, 4–6]. 
IgG N-glycosylation impacts the physiology and malfunc-
tion of the immune system, and aberrant IgG N-glyco-
sylation is involved in several inflammatory and chronic 
diseases [7–10]. Previous studies have revealed that 
genetic loci associated with variation in IgG glycosyla-
tion are also known risk factors for several inflammatory 
diseases and chronic diseases [11, 12], indicating that 
IgG glycosylation is not merely a result of complicated 
enzymatic activities, but is a subtly regulated outcome 
designed to meet dominant physiological needs.
It is widely recognized that dyslipidaemia is associated 
with an increased risk of coronary artery disease, stroke, 
and heart failure [13–16]. However, the mechanisms by 
which dyslipidaemia increase the risk of these diseases 
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has not been completely elucidated. Importantly, dyslipi-
daemia is responsive to changes in systemic inflamma-
tion, a recognized causal pathway of cardiovascular and 
cerebrovascular diseases [17–22]. Epidemiological evi-
dence has indicated that blood lipids are associated with 
several inflammatory markers, such as cytokines and 
chemokines [17, 23]. Due to the inflammatory role of IgG 
N-glycosylation, together with its association with ageing 
[24], obesity [25], type 2 diabetes [26], hypertension [27, 
28], ischemic stroke [29], Parkinson’s disease [30] and 
cancer [31], it can be speculated that blood lipids may be 
associated with the N-glycosylation of IgG.
In this study, we aimed to determine the association 
between the IgG N-glycome and blood lipids, includ-
ing total cholesterol (TC), total triglycerides (TG), high-
density lipoprotein (HDL), and low-density lipoprotein 
(LDL), and explored the use of IgG glycans as biomarkers 
to diagnose dyslipidaemia to further investigate the role 
of IgG glycosylation in dyslipidaemia.
Methods
Ethical approval
Written informed consent was obtained from each sub-
ject at the beginning of the study, and the study has been 
approved by the Ethics Committee of the Capital Medical 
University, Beijing, China. The ethics approval was given 
in compliance with the Declaration of Helsinki [32].
Participant recruitment
An observational cross-sectional study was conducted 
during 2012, with a total of 913 participants of Chinese 
Han ancestry who were recruited from a community-
based survey in Beijing [24, 27]. All participants were 
required to meet the following inclusion criteria: (1) 
age equal to or greater than 18  years; (2) no medica-
tion history during the previous 2 weeks; and (3) signed 
informed consent prior to participation. Individuals were 
excluded based on the following criteria: (1) pregnant or 
lactating women; (2) history of mental illness or infec-
tious disease; and (3) history of malignant tumor, stroke 
or other cerebrovascular disease, congenital heart dis-
ease, acute myocardial infarction, liver disease, renal fail-
ure, chronic obstructive pulmonary disease, rheumatoid 
arthritis or other disease.
Diagnosis of dyslipidaemia
According to the Chinese guidelines for the prevention 
and control of dyslipidaemia in adults [33], the partici-
pants were grouped into cases with TC ≥ 6.2  mmol/L 
(defined as hypercholesteremia), TG ≥ 2.3  mmol/L 
(defined as hypertriglyceridemia), HDL < 1.0  mmol/L 
(defined as the decreased HDL), or LDL ≥ 4.1  mmol/L 
(defined as the elevated LDL). The controls were those 
who did not have dyslipidaemia at the time of the study.
Covariates
Each participant was required to complete a thorough 
health examination, which included anthropometric 
measurements and an analysis of the physical and chemi-
cal properties of a blood sample. Detailed information 
about subject recruitment and enrolment has been pre-
viously described [24, 27]. As in our previous study [24], 
12 clinical traits (age, sex, body mass index (BMI), waist–
hip ratio (WHR), systolic blood pressure (SBP), diastolic 
blood pressure (DBP), fasting blood triglycerides (FBG), 
resting heart rate (RHR), TC, TG, HDL and LDL) were 
assessed in the current study [24].
To obtain the anthropometric trait data, physical 
examinations and interviews were carried out by trained 
nurses and physicians. The BMI was calculated by the for-
mula weight (in kilograms)/height2 (in metres squared). 
The SBP and DBP were measured twice on the right arm 
using a standard mercury sphygmomanometer after the 
subjects had rested for at least 10 min in a sitting posi-
tion [34]. For the blood parameters (haematology and 
biochemical traits), fasting blood samples were collected 
in the morning after an overnight fast by venepuncture. 
All collected blood samples were processed within 8  h 
and blood plasma which was separated from whole blood 
was stored in freezers (− 80  °C) before the measure-
ments. Haematology and biochemical parameters were 
measured by standard blood chemistry and haematology 
assays (Hitachi Automatic Analyzer, Model-7600, Tokyo, 
Japan), which were conducted at the Medical Laboratory 
of Beijing Xuanwu Hospital, Beijing.
IgG N‑glycan analysis
As previously reported, IgG was first isolated from 
human plasma [24, 35]. The IgG N-glycans were cleaved 
and analysed by hydrophilic interaction chromatogra-
phy (HILIC)- ultra-performance liquid chromatogra-
phy (UPLC) as previously described [35]. In brief, after 
washing and equilibrating the protein G monolithic 
plates, 50  µL of plasma was diluted 10× with binding 
buffer (1× phosphate-buffered saline, pH 7.4), applied to 
the protein G plates, and immediately washed. The IgGs 
were eluted with 1 mL of 0.1 M formic acid and imme-
diately neutralized with 1  M ammonium bicarbonate. 
Next, the IgG N-glycans cleavage and labelling were 
performed. The released N-glycans were labelled with 
2-aminobenzamide, a fluorescent dye used to visualize 
glycans by UPLC, by multistage mixing with 2-amin-
obenzamide, dimethyl sulfoxide, glacial acetic acid, and 
2-picoline borane. Finally, the IgG N-glycans were ana-
lysed by HILIC–UPLC in 24 IgG glycan peaks (GPs). The 
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glycan structures of the glycans per peak were previously 
reported, and a detailed description is shown in Addi-
tional file 1: Table S1 [35]. The normalization and batch 
correction of the UPLC data was detailed in a previous 
study [24, 35]. The total area normalization was applied 
where the amount of glycans in each peak was expressed 
as a percentage of the total integrated area. The calcula-
tion formula is shown in Additional file 1: Table S1.
Among the 24 initial GPs, GP3 was excluded as it did 
not pass quality control tests. An additional 54 derived 
traits were calculated for the remaining 23 initial glycans 
[35]. Of the derived traits, 34 were of interest and were 
included in the analysis describing the relative abun-
dances of galactosylation, sialylation, bisecting GlcNAc 
and core fucosylation (Additional file 2: Table S2).
Statistical analysis
The normal distribution of glycans was tested by the Kol-
mogorov–Smirnov test where P < 0.10 was considered to 
be statistically significant. Continuous variables under-
lying the normal distribution were represented as the 
mean ± standard deviation (SD), otherwise the medians 
(interquartile ranges) were used. The difference of con-
tinuous variables between two groups was tested using 
Student’s t test or the Wilcoxon rank-sum test. Categori-
cal variables were represented as n (proportion), and the 
between-group differences were tested by the Chi square 
test. For the normally distributed variables, including age, 
BMI, WHR, SBP, DBP, FBG and RHR, t-tests were used 
to compare the differences between two groups. A gen-
eralized linear model (GLM) [36] was fitted to estimate 
the effect of blood lipids on glycosylation when adjusting 
for confounding factors, including age, sex, BMI, WHR, 
SBP, DBP, FBG and RHR, because most of the glycans 
(dependent variables) were not normally distributed. 
There were internal associations among the independent 
variables, which could have induced multi-collinearity 
in the statistical models. Therefore, principal compo-
nent analysis (PCA) [37] was used to combine variables 
to principal components before the regression analysis. 
Moreover, these principal components were used in the 
multiple variables association analysis instead of the orig-
inal variables. The internal associations among the inde-
pendent variables were analysed using by the R package 
“corrplot” [38].
Before correlation and regression analysis, the z-score 
of normalized transformations for IgG N-glycans was 
applied to add the consistent comparability among IgG 
N-glycans. Canonical correlation analysis (CCA) [40] was 
used to determine two sets of variables of the initial gly-
can structures (x) and the blood lipids (y) and to find the 
overall correlation between the two sets of variables. The 
identified variables with a statistically significant impact 
on the canonical variables were judged by the canonical 
loadings. Generally, absolute values greater than 0.30 are 
considered to be significant loadings [39].
To explore IgG N-glycans as biomarkers to diagnose 
dyslipidaemia, 23 initial glycans were used as predic-
tors. Logistic regression was performed to identify the 
23 glycans that were respectively related to cases’ sta-
tus after adjusting for the effect of age, sex, BMI, WHR, 
SBP, DBP, FBG and RHR. Considering the internal asso-
ciations among these variables, we chose to correct sex, 
Prin.1 and Prin.2 instead of the original variables. The 
significant glycans were presented as the odds ratio (OR) 
with a 95% confidence interval (CI) and were graphed 
by a forest plot, which was generated using the R pack-
age “forestplot” [40]. Next, a classification model was 
established based on the significant glycans. Considering 
that there were internal associations in the glycans that 
might have induced multicollinearity in the model, the 
least absolute shrinkage and selection operator (LASSO) 
method was used to select glycans to reduce the dimen-
sion of data. The LASSO method was carried out by the 
R package “lars” [41]. The logistic regression model was 
then used to assess the discrimination of dyslipidaemia 
by combining the glycans left by the LASSO method. The 
classification model was only used to assess the ability of 
IgG N-glycans to be used as diagnostic biomarkers for 
disease; therefore, in the classification model there was 
no adjustment for the effect of age, sex, BMI, WHR, SBP, 
DBP, FBG and RHR. A receiver operating characteristic 
(ROC) curve was developed for the calculation of the 
area under the cure (AUC) with a 95% CI.
Data analysis was performed using SPSS Statistics 
version 21.0 for Windows (IBM Corp., Armonk, NY, 
USA), SAS software version 9.2 (SAS Institute, Chi-
cago, IL, USA) and R version 3.3.2 (R Core Team 2016). 
All reported P values were two-sided, and P < 0.05 
was considered statistically significant. Particularly, 
P < 0.05/57 (0.0009) was considered to be statistically sig-
nificant in the analysis of glycans to correct for multiple 
comparisons.
Results
Description of clinical traits
Among the 913 recruited participants, 598 (64.50%) had 
a complete dataset of blood measurements and glycan 
traits and were included in the further analysis. In total, 
8 clinical traits were described and compared between 
the dyslipidaemia and control groups (Table 1). Most of 
the traits (6 out of 8) were significantly different between 
the two groups (P < 0.05). The number of males and the 
values of age, BMI, WHR, FBG, and SBP in the dyslipi-
daemia group were significantly higher than those in the 
control group.
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Principal component analysis (PCA)
As shown in Additional file  3: Figure S1, the significant 
correlation coefficients in independent variables ranged 
from 0.08 to 0.89. PCA was used to combine a few vari-
ables to several principal components in order to reduce 
the multicollinearity of independent variables. The result-
ing Prin. 1 and Prin. 2 explained up to 54.78% of variance 
in SBP, DBP, FBG, RHR, age, BMI and WHR (Prin.1 = 0.7
73 × SBP + 0.783 × DBP + 0.575 × FBG + 0.106 × RHR + 
0.352 × Age + 0.688 × BMI + 0.733 × WHR, Prin.2 = 0.3
61 × SBP + 0.364 × DBP − 0.176 × FBG + 0.739 × RHR − 
0.370 × Age − 0.246 × BMI − 0.329 × WHR). The result-
ing Prin. 3 and Prin. 4 explained up to 85.65% of variance 
in TC, TG, HDL and LDL (Prin.3 = 0.985 × TC + 0.134 
× TG + 0.444 × HDL + 0.923 × LDL, Prin.4 = 0.133 × TC 
+ 0.889 × TG − 0.755 × HDL + 0.092 × LDL). Therefore, 
in the analysis of the association between IgG N-glycans 
and blood lipids, the principal components of blood 
lipids (Prin. 3 and Prin. 4) were used as independent vari-
ables instead of blood lipids, and they were adjusted for 
confounding factors (sex, Prin. 1 and Prin. 2).
The association of IgG N‑glycans with blood lipids
The results of the normal distribution tests of glycans are 
shown in Additional file  4: Table  S3. Of the 23 directly 
measured glycans, 16 were not abnormally distributed 
(P < 0.10). Therefore, a GLM was used to estimate the 
effect of the principal components of blood lipids (Prin. 
3 and Prin. 4) on glycosylation, adjusting for confound-
ing factors (sex, Prin. 1 and Prin. 2). In total, 2 GPs in 
the IgG N-glycans were significantly associated with 
blood lipids after adjusting for the effects of sex, age, 
BMI, WHR, FBG, RHR, SBP and DBP (P < 0.05/57). As 
shown in Table 2, TC, TG and LDL were positively cor-
related with GP6, while they were negatively correlated 
with GP18. In addition, HDL negatively correlated with 
GP6 but positively correlated with GP18. Furthermore, 9 
initial traits and 7 derived traits in the IgG glycome were 
significantly associated with blood lipids after adjusting 
for the effects of sex, age, BMI, WHR, FBG, RHR, SBP 
and DBP (P < 0.05). Detailed information is shown in the 
supplemental content (Additional file 5: Table S4).
Multivariate analyses by canonical correlation analysis 
(CCA)
The results of CCA showed that there are 4 pairs of 
canonical variables, with canonical correlations of 0.390 
(F = 2.44, P < 0.001), 0.324 (F = 1.88, P < 0.001), 0.240 
(F = 1.39, P = 0.053) and 0.197 (F = 1.16, P = 0.282) for 
each successive pair by the CCA. The first and the sec-
ond canonical sets were statistically significant, indicat-
ing that N-glycan structures were significantly correlated 
with the blood lipids. As shown in Fig. 1, 10 initial traits 
(GP4, GP6, GP9-12, GP14, GP17-18 and GP23) tended to 
be significantly associated with TC, TG and LDL levels in 
the first canonical set. In addition, the level of GP11 was 
strongly associated with canonical variables with a load-
ing of 0.645, while the response variable with the highest 
canonical loading was 0.781 (TC).
Classification of dyslipidaemia using IgG N‑glycans
Among the 23 GPs, 9 GPs (GP1, GP4, GP5, GP6, GP11, 
GP14, GP18, GP20 and GP21) were found to be signifi-
cantly different in participants with dyslipidaemia than 
in controls after adjusting for confounding factors (sex, 
Prin. 1 and Prin. 2) (Fig. 2 and Additional file 6: Table S5). 
As shown in Additional file  7: Figure S2, the significant 
correlation coefficients in independent variables ranged 
from 0.11 to 0.79. The LASSO method was used to select 
IgG N-glycans in order to reduce the dimension of data. 
The remaining glycans used by the LASSO method are 
listed in Additional file  8: Table  S6. The classification 
model, incorporating significant IgG N-glycans, was able 
to distinguish dyslipidaemia from controls, and the AUC 
was 0.692 (95% CI 0.644–0.740) (Fig. 3).
Table 1 Demographic and biochemical characteristics of the participants
BMI body mass index, WHR waist–hip ratio, FBG fasting blood triglycerides, SBP systolic blood pressure, DBP diastolic blood pressure, RHR resting heart rate
* Statistically significant at significant level of 0.05
Parameters Total (n = 598) Dyslipidaemia (n = 150) Controls (n = 448) P*
Number of male (%) 198 (33.11%) 76 (50.67%) 122 (27.23%) < 0.001
Age (years) 47.35 ± 6.59 48.89 ± 7.02 46.84 ± 6.36 0.001
BMI (kg/m2) 24.59 ± 3.23 25.43 ± 3.65 24.28 ± 3.04 < 0.001
WHR 0.82 ± 0.07 0.85 ± 0.07 0.81 ± 0.07 < 0.001
FBG (mmol/L) 5.35 ± 0.83 5.58 ± 0.99 5.29 ± 0.77 < 0.001
SBP (mmHg) 117.69 ± 14.05 119.50 ± 13.84 117.26 ± 15.06 0.108
DBP (mmHg) 78.78 ± 10.46 82.06 ± 10.87 77.93 ± 10.20 < 0.001
RHR (beats/min) 76.09 ± 9.59 76.29 ± 8.91 76.13 ± 9.73 0.859
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Discussion
Dyslipidaemia is one of the most important risk factors 
for atherosclerosis, which triggers the development of 
various cardiovascular and cerebrovascular diseases [13–
16]. The increased TC, TG and LDL and the decreased 
HDL could be major public health problems; therefore, 
the identification of biomarkers that might provide new 
avenues for the prevention and treatment of dyslipidae-
mia is urgently needed. To our knowledge, this is the first 
study to investigate the association of IgG N-glycans with 
blood lipids and dyslipidaemia.
In the present study, the levels of TC, TG and LDL 
were positively associated with the levels of GP4 and 
GP6, while they were negatively correlated with the 
level of GP18. Furthermore, the results were consistent 
with those in CCA, in which N-glycan structures were 
related with blood lipids. GP4 and GP6 are agalacto-
sylated glycans and share the derived trait  G0n, which 
contains nearly the all glycans without galactose. In 
parallel, GP18 contains 2 galactoses, which was nega-
tively correlated with blood lipids. In addition, GP6 that 
contains a bisecting GlcNAc was positively associated 
with blood lipids, while a significant negative correla-
tion existed between blood lipids and GP18, in which 1 
sialic acid was found. This is consistent with the results 
of the association between the derived traits in the IgG 
glycome and blood lipids. Our findings indicated that 
the associations between the blood lipids and IgG gly-
come were independently significant, with a negative 
association with diagalactosylation and sialylation and 
a positive association with bisecting agalactosylation 
and N-acetylgucosylation. Furthermore, the loss of 
galactose and sialic acid and the addition of a bisect-
ing GlcNAc were consistently observed in patients with 
dyslipidaemia. The changes of IgG N-glycosylation in 
dyslipidaemia are consistent with the results of type 2 
Table 2 Associations between IgG glycan and blood lipids
Prin.1 = 0.773 × SBP + 0.783 × DBP + 0.575 × FBG + 0.106 × RHR + 0.352 × Age + 0.688 × BMI + 0.733 × WHR
Prin.2 = 0.361 × SBP + 0.364 × DBP − 0.176 × FBG + 0.739 × RHR − 0.370 × Age − 0.246 × BMI − 0.329 × WHR
Prin.3 = 0.985 × TC + 0.134 × TG + 0.444 × HDL + 0.923 × LDL
Prin.4 = 0.133 × TC + 0.889 × TG-0.755 × HDL + 0.092 × LDL
BMI body mass index, WHR waist–hip ratio, FBG fasting blood glucose, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, TG total 
triglycerides, HDL high-density lipoprotein, LDL low-density lipoprotein, RHR resting heart rate
a Adjusted for the effects of sex, Prin.1, Prin.2 and Prin.4
b Adjusted for the effects of sex, Prin.1, Prin.2 and Prin.3
* Statistically significant associations between two variables are shown, P < 0.05
** Statistically significant associations between two variables are shown, P < 0.05/57 = 0.0009
IgG glycans Prin. 3 Prin. 4
β (95% CI)a P β (95% CI)b P
Initial measurements
 GP2 0.046 (0.006 to 0.087) 0.023* − 0.012 (− 0.055 to 0.032) 0.596
 GP4 0.035 (0.014 to 0.056) 0.001* − 0.015 (− 0.039 to 0.010) 0.237
 GP5 0.035 (0.014 to 0.055) 0.001* 0.019 (− 0.006 to 0.044) 0.130
 GP6 0.036 (0.015 to 0.057) < 0.001** − 0.010 (− 0.034 to 0.014) 0.395
 GP11 0.020 (0.004 to 0.036) 0.013* 0.017 (− 0.001 to 0.035) 0.066
 GP14 − 0.022 (− 0.037 to 0.006) 0.006* 0.004 (− 0.014 to 0.022) 0.642
 GP18 − 0.033 (− 0.051 to 0.015) < 0.001** 0.006 (− 0.015 to 0.026) 0.604
 GP20 0.014 (− 0.015 to 0.042) 0.336 0.051 (0.018 to 0.084) 0.003*
 GP21 0.024 (0.004 to 0.045) 0.020* 0.025 (0.001 to 0.049) 0.041*
Sialylation
 FGS/(FG + FGS) − 0.014 (− 0.025 to 0.003) 0.013* 0.001 (− 0.011 to 0.014) 0.840
 FGS/(F + FG + FGS) − 0.023 (− 0.037 to 0.008) 0.003* 0.006 (− 0.012 to 0.023) 0.527
Bisecting GlcNAc
 FBStotal/FStotal 0.021 (0.002 to 0.041) 0.032* − 0.008 (− 0.030 to 0.014) 0.498
 FBS2/FS2 0.020 (0.001 to 0.038) 0.039* 0.005 (− 0.016 to 0.023) 0.660
 FBS2/(FS2 + FBS2) 0.011 (0.001 to 0.020) 0.034* 0.002 (− 0.009 to 0.013) 0.740
Galactosylation
 G0n 0.029 (0.012 to 0.046) 0.001* –0.013 (− 0.033 to 0.007) 0.212
 G2n − 0.026 (− 0.043 to 0.009) 0.003* 0.008 (− 0.013 to 0.027) 0.476
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Fig. 1 Canonical structures of the normalized IgG N‑glycan and blood lipids in the first canonical set. The absolute value of canonical loadings 
greater than 0.30 was significant loadings. All of the variables are sorted by the absolute value of their canonical loadings. The positive relationships 
are represented in black boxes, while negative relationships are showed in red boxes. TC total cholesterol, TG total triglycerides, HDL high‑density 
lipoprotein, LDL low‑density lipoprotein
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diabetes, hypertension and ischemic stroke [26, 27, 29, 
42].
N-Glycans that are attached to the Fc portion of IgG 
are important modulators of IgG effector functions [5], 
and even slight changes in IgG glycosylation can direct 
pro- and anti-inflammatory actions of immunoglobu-
lins [1, 4]. The decreased IgG galactosylation in rheuma-
toid arthritis was first reported nearly 32 years ago [43], 
and recently, the same type of change in IgG glycosyla-
tion has been reported in a number of autoimmune and 
inflammatory diseases [7, 9, 10, 12]. In addition, IgG gly-
cosylation correlates with ageing, obesity, hypertension 
and cancer [24, 25, 27, 31]. It can be speculated that the 
loss of galactose is not disease specific but is a general 
phenomenon that is associated with reducing the anti-
inflammatory function of circulating IgG. The addition 
of sialic acid dramatically changes the physiological role 
of IgGs, converting them from pro-inflammatory to anti-
inflammatory agents [6, 44]. In the interactions between 
different functional elements of IgG glycosylation, it 
has been shown that the presence of bisecting GlcNAcs 
reduce galactosylated IgGs [6, 45, 46]. Accumulating evi-
dence indicates that changes in IgG glycosylation mecha-
nism could be part of the molecular mechanism leading 
to the promotion of inflammation [6, 8, 44, 47]; therefore, 
our results indicate inflammation as one of characteris-
tics in dyslipidaemia that can increase the risk of develop-
ing other related disorders. This hypothesis is supported 
by our findings that IgG N-glycosylation is significantly 
associated with blood lipids and dyslipidaemia.
Previous studies have shown that the inflammatory role 
of IgG N-glycosylation is associated with the risk factors 
of dyslipidaemia [48] including aging and obesity [24, 
25]. Inflammation, which is characteristic of aging and 
obesity, is a process associated with different disorders, 
such as dyslipidaemia [49]. Inflammatory disorders can 
lead to the activation of several signalling transduction 
pathways, inflammatory cytokine chemokine produc-
tion and cell migration, all of which can influence lipid 
Fig. 2 Odds ratios (OR) and 95% confidence intervals (95% CI) for the associations of the normalized glycan variables in dyslipidaemia vs controls 
(adjusted for sex, Prin.1 and Prin.2)
Fig. 3 Receiver operating characteristic (ROC) curve analysis in 
regard to binary logistic regression in the prediction of dyslipidaemia. 
AUC area under the cure; GP4, GP6, GP14, GP18, GP20 and GP21 
included in the final model
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metabolism [49–52]. Interleukin 6 (IL-6) has been impli-
cated in the pathogenesis of several immune-mediated 
diseases, and monoclonal antibodies directed against 
the IL-6 receptor have been developed to treat different 
inflammatory diseases [53]. IL-6 and interleukin 6 signal 
transducer (IL6ST) have been identified as dyslipidaemia 
susceptibility loci [54, 55]. IL6ST has been identified to 
have the capability to regulate galactosylation of IgG in 
a genome-wide association study of IgG N-glycosylation 
[12]. According to the law of Mendelian randomization 
[56, 57], the genetic loci IL6ST is associated with IgG 
N-glycosylation and has an effect on dyslipidaemia, indi-
cating that the change of galactosylation and inflamma-
tion is the intermediate phenotype between IL6ST and 
dyslipidaemia and is thus the causal factor of dyslipidae-
mia. However, this will need to be further explored and 
validated.
The aberrant glycosylation which induces inflamma-
tion may provide exciting insights into the pathogenesis 
of dyslipidaemia. However, causation is difficult to verify, 
and the observed changes may be the consequence rather 
than cause of the disease. Dyslipidaemia accompanied by 
adipocytes that can produce and secrete cytokines and 
adipokines [58] may thus affect the structural integrity 
of IgG glycans, where IgG plays a crucial role in the acti-
vation of complement, interacts with Fc receptors and 
affects antibody-dependent cell mediated cytotoxicity 
(ADCC) [5]. Dyslipidaemia, as a basic metabolic disease, 
may trigger changes in IgG glycosylation accompanied by 
inflammation that can lead to related diseases. Therefore, 
the casual effect between IgG glycosylation and dyslipi-
daemia remains unclear.
There are several potential limitations in this study that 
should be recognized. First, the study was performed 
with a relatively small sample population. Multiple cor-
rection was not used when we selected the initial glycans 
as diagnostic biomarkers, which may have led to false 
positive errors. However, to overcome this, the method 
of reducing the dimensions of data, including PCA and 
CCA, were applied to examine the association between 
level of N-glycans and blood lipids. The merit of PCA is 
that it explores all of the information from principal com-
ponents, while the merit of CCA is to explore all of the 
information from two sets of variables; therefore, PCA 
and CCA help to solve the problem of multicollinearity 
that is induced by the similarities of the variables. Sec-
ond, our study is a cross-sectional study, bringing the 
bias of diagnosis of dyslipidaemia cases. It lacks informa-
tion regarding the time sequence of events; therefore, we 
cannot conclude the causal relationship of IgG glycosyla-
tion and dyslipidaemia. In addition, the present study is 
a pilot study to explore the association between N-gly-
cans and blood lipids and dyslipidaemia. Further cohort 
studies or Mendelian randomization studies [57, 58] with 
larger sample sizes are needed to provide a more definite 
explanation about the relationships between N-glycan 
structures and dyslipidaemia.
Conclusion
In conclusion, the present study showed a possible asso-
ciation between blood lipids and the observed loss of 
galactose and sialic acid, as well as the addition of bisect-
ing GlcNAcs which might be related to the chronic 
inflammation accompanying the development of dys-
lipidaemia. Moreover, IgG N-glycosylation profiles may 
serve as potential biomarkers for dyslipidaemia, contrib-
uting to a move towards personalized medicine. Future 
studies focused on the mechanisms underlying the causal 
association of IgG glycosylation and blood lipids or dys-
lipidaemia are needed.
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